Table 3.
Sequencing analysis of biliary tract cancers using EUS-FNA/FNB
| Year | References | Patient number | Cancer type | Sampling methods | Analysis methods | Analysis target | Success rate of sequencing analysis | Detection rate of actionable mutations |
|---|---|---|---|---|---|---|---|---|
| 2016 | Gleeson et al. [40] | 4 | AC (4) | FNA | Targeted seq | 160 genes | ND | ND |
| 2017 | Choi et al. [103] | 13 |
IHCC (7) GBC (5) AC (1) |
FNB |
PNA-PCR Targeted seq |
KRAS | ND | ND |
| 2019 | Hirata et al. [100] | 21 |
IHCC (6) EHCC (3) GBC (12) |
FNA | Targeted seq | 50 genes | 95.2% | 33% |
| 2021 | Kai et al. [101] | 12 |
IHCC (3) EHCC (2) GBC (7) |
FNA | Targeted seq | MSI | 100% | 0% |
| 2021 | Maruki et al. [102] | 26 | ND | FNA | FISH + targeted RNA seq | FGFR2 | ND | 7.7% |
ND not described, EUS endoscopic ultrasound, FNA fine-needle aspiration, FNB fine-needle biopsy, seq sequence, PNA peptide nucleic acid, PCR polymerase chain reaction, FISH fluorescent in situ hybridization, AC ampullary cancer, IHCC intrahepatic cholangiocarcinoma, GBC gallbladder carcinoma, EHCC extrahepatic cholangiocarcinoma, MSI microsatellite instability